from the world's big
The prevalence of Alzheimer’s disease is expected to triple over the next three decades, to nearly 14 million in the United States alone.
Last summer, a research group from the University of California, Los Angeles (UCLA) quietly published the results of a new approach in the treatment of Alzheimer’s disease. What they found was striking. Although the size of the study was small, every participant demonstrated such marked improvement that almost all were found to be in the normal range on testing for memory and cognition by the study’s end. Functionally, this amounts to a cure.
Why do first-world ailments get cured faster than global health crises? Because Big Pharma doesn’t serve sick people, it serves rich people—let's change that.
One of the world's open secrets is that we don't look after all sick people in the same way. Why does back pain in the U.S. get a treatment developed faster than fatal dysentery in Central Africa? It's not a huge riddle: research and development programs of the pharmaceutical industry treat the diseases and ailments that will turn the highest profit. To solve a problem this large and unjust, Nicole Hassoun, a residential fellow with the Hope & Optimism Project at Cornell University, is employing the virtue she terms 'creative resolve'. When obstacles get in our way, Hassoun says we need to think innovatively about how can we change the problem or look at it differently. If we can't appeal to Big Pharma's better nature, then we have to come up with more creative solutions. And Hassoun has one: fair trade pharmaceuticals. Here, she explains her idea to incentivize cheaper drugs and medical access to combat global health crises. This video was filmed as part of the Los Angeles Hope Festival, a collaboration between Big Think and Hope & Optimism.
British doctors eliminate the disease in two infants with incurable cancer by utilizing a medical first gene-editing techniques.
A group of British doctors successfully eliminated cancer in two infants with leukemia by using genetically modified immune cells from a donor. The accomplishment opens a new age of cancer therapy treatment.